Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?

C. Formichi,W. Baronti,G. de Gennaro,M. Cerrai Ceroni,L. Nigi,L. Rizzo,F. Dotta
DOI: https://doi.org/10.1007/s40618-024-02369-4
2024-04-29
Journal of Endocrinological Investigation
Abstract:Abstract Purpose To evaluate the variables influencing the therapeutic choice toward oral versus subcutaneous semaglutide in a cohort of diabetic subjects. Methods We retrospectively collected data of 292 patients followed at the Diabetes Unit of the University Hospital of Siena and the Hospital of Grosseto, who were prescribed oral (n = 115) or subcutaneous (n = 177) semaglutide between October 2021 and October 2022. Results Oral semaglutide was preferentially prescribed in older subjects with longer disease duration in replacement of other antidiabetic drugs, while subcutaneous semaglutide was preferentially prescribed in add-on to metformin in subjects with higher body weight and BMI. After 6 months, both formulations significantly improved glycemic control and body weight, however injectable semaglutide showed a greater efficacy on A1c levels, weight loss, BMI and waist circumference reduction. No differences were found in terms of adverse events. Conclusion In our experience, injectable semaglutide is preferred in patients with excess weight and shorter disease duration, while the oral formulation was used later and especially after therapeutic failure of previous therapies. Follow-up data indicate similar tolerability and efficacy of both formulations, despite subcutaneous semaglutide demonstrated greater efficacy.
endocrinology & metabolism
What problem does this paper attempt to address?
### Problems the Paper Attempts to Solve This paper aims to evaluate the factors influencing the choice of oral versus subcutaneous semaglutide treatment in diabetic patients. Specifically, the researchers hope to understand, through retrospective analysis, which variables determine the choice of these two different administration forms by doctors and patients in real clinical practice. ### Research Background Semaglutide is an effective glucagon-like peptide-1 receptor agonist (GLP1-RA) used to treat type 2 diabetes (T2D). It comes in two forms: oral and subcutaneous injection. Although both forms have shown good efficacy and safety in clinical trials, the choice between these forms in actual clinical practice may be influenced by various factors. ### Research Methods The researchers collected data from 292 patients treated at the diabetes departments of the University Hospital of Siena and Grosseto Hospital in Italy between October 2021 and October 2022. These patients were divided into two groups: 115 patients received oral semaglutide, and 177 patients received subcutaneous semaglutide. Through retrospective analysis, the researchers compared the baseline characteristics, treatment regimens, efficacy, and adverse reactions of the two groups. ### Main Findings 1. **Baseline Characteristics**: - Oral semaglutide was mainly prescribed to older patients with a longer disease duration as a replacement for other antidiabetic medications. - Subcutaneous semaglutide was mainly prescribed to patients with higher weight and BMI as an adjunct to metformin. 2. **Efficacy**: - Both forms of semaglutide significantly improved glycemic control and weight after 6 months. - Subcutaneous semaglutide showed higher efficacy in reducing A1c levels, weight, BMI, and waist circumference. 3. **Adverse Reactions**: - There were no significant differences in adverse reactions between the two forms of semaglutide, mainly presenting as mild to moderate gastrointestinal symptoms such as nausea, vomiting, constipation, diarrhea, or bloating. ### Conclusion In actual clinical practice, subcutaneous semaglutide is more commonly used in overweight patients with a shorter disease duration, while oral semaglutide is more often used in older patients with previous treatment failures. Although subcutaneous semaglutide performs better on certain indicators, both forms of semaglutide are similar in tolerability and overall efficacy. ### Significance This study provides practical references for doctors when choosing between oral and subcutaneous semaglutide, helping to better personalize treatment plans, improve patient compliance, and enhance treatment outcomes.